Existing Partners
Advaxis’s global partnering strategy is to leverage the versatility of its Lm-LLO proprietary cancer immunotherapy technology and partner with other biopharmaceutical companies. Advaxis will use its immunotherapies – either alone or in combination with other immunotherapies – to develop and commercialize its immunotherapies worldwide.
Advaxis has established clinical collaborations for its proprietary Lm-LLO immunotherapies with the following biopharmaceutical industry leaders:
Merck and Company
Advaxis and Merck have established a clinical trial collaboration to evaluate the safety and efficacy of Merck’s investigational monoclonal antibody against PD-1 in combination with Advaxis’s investigational Lm-LLO immunotherapy (ADXS-PSA) as a treatment for patients with previously treated metastatic, castration-resistant prostate cancer.
Merck is one of the largest pharmaceutical companies in the world and a leading research-driven healthcare company.
AstraZeneca / MedImmune
Advaxis and MedImmune have established a clinical trial collaboration to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor in combination with Advaxis’s investigational Lm-LLO immunotherapy, axalimogene filolisbac (ADXS-HPV) as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and head and neck cancer.
MedImmune is the global biologics research and development arm of AstraZeneca, one of the largest pharmaceutical companies with a focus in oncology.
Incyte Corporation
Advaxis and Incyte have established a clinical trial collaboration to evaluate the safety and efficacy of Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in combination Advaxis's Lm-LLO cancer immunotherapy, axalimogene filolisbac as a treatment for patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.
Incyte is a leading biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs, primarily for oncology.
Sorrento Therapeutics
Advaxis and Sorrento Therapeutics have entered into a non-exclusive research and clinical trial collaboration agreement to evaluate combinations of Advaxis’s Lm-LLO cancer immunotherapy technology platform, including axalimogene filolisbac, ADXS-PSA, ADXS-HER2, with Sorrento’s fully human antibodies targeting immune checkpoints, including GITR, OX40, LAG-3 and TIM-3.
Sorrento is an oncology company developing new treatments for cancer and associated pain. They have one of the largest and most diverse fully human antibody libraries in the industry designed to facilitate rapid identification and selection of highly specific therapeutic monoclonal antibody product candidates.
Advaxis has exclusively licensed certain constructs of its Lm-LLO proprietary immunotherapies to the following biopharmaceutical industry leaders for both human and animal therapeutics:
Aratana
Advaxis has granted Aratana an exclusive license for the development and commercialization of Advaxis’s investigational Lm-LLO immunotherapy (ADXS-cHER2) for osteosarcoma and three other Lm-LLO immunotherapy product candidates for three other cancers in canines and felines. Aratana is responsible for all manufacturing, clinical development, regulatory and commercial costs.
Aratana is a dominant pet therapeutics company focused on the licensing, development, and commercialization of innovative biopharmaceutical products for cats, dogs, and other companion animals.
Biocon
Advaxis has granted Biocon an exclusive license for the development and commercialization of Advaxis’s investigational Lm-LLO immunotherapy, axalimogene filolisbac for the treatment of cervical cancer in India. Biocon is responsible for all regulatory and commercial cost and activities associated with axalimogene filolisbac in India and key territories. Biocon is India's largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services.
Cervical cancer is one of the most frequent cancers in women in India. It is estimated that every year over 134,000 women are diagnosed with cervical cancer in India and nearly 73,000 die from this disease, according to WHO statistics and the Cervical Cancer (HPV Information Centre) 2010.
Global BioPharma
Advaxis has granted Global BioPharma an exclusive license for the development and commercialization of Advaxis’s investigational Lm-LLO immunotherapy, axalimogene filolisbac for the treatment of cervical cancer in Asia. Global BioPharma is responsible for all development and commercial costs and activities associated with the licensed product in Asian territories. Global BioPharma is a Taiwanese biotechnology company funded by a group of investors led by Taiwan Biotech Co., Ltd., a top five pharmaceutical company in Taiwan.
The Global BioPharma’s territory covers over 4 billion people with over 200,000 annual diagnoses of cervical cancer, accounting for roughly 40% of the world’s cases, according to WHO statistics.
